Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 5Carcinoma, Neuroendocrine 5Thyroid Neoplasms 2Adrenocortical Carcinoma 2Vulvar Neoplasms 1Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thyroid Cancer, Papillary 1Somatostatinoma 1Small Cell Lung Carcinoma 1Seminoma 1Sarcoma 1Rare Diseases 1Pseudomyxoma Peritonei 1Pituitary Neoplasms 1Pituitary Diseases 1Pheochromocytoma 1Perivascular Epithelioid Cell Neoplasms 1Penile Neoplasms 1Parathyroid Neoplasms 1Paranasal Sinus Neoplasms 1Paraganglioma 1Paget Disease, Extramammary 1Ovarian Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Histiocytoma, Malignant Fibrous 1

Interventions

Nivolumab 1Ipilimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Genital Neoplasms, Female × Ipilimumab × Endocrine × Clear all
NCT04969887 2026-02-27

MOST-CIRCUIT

Olivia Newton-John Cancer Research Institute

Phase 2 Active not recruiting
240 enrolled
EndocrineNET

Genital Neoplasms, Female, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡